Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021

Authors

  • Christiane Stehmann Florey Institute, The University of Melbourne, Victoria, 3010, Australia
  • Matteo Senesi Department of Medicine, The University of Melbourne, Victoria, 3010, Australia
  • Shannon Sarros Florey Institute, The University of Melbourne, Victoria, 3010, Australia
  • Amelia McGlade Florey Institute, The University of Melbourne, Victoria, 3010, Australia
  • Victoria Lewis Department of Medicine, The University of Melbourne, Victoria, 3010, Australia
  • Marion Simpson Florey Institute, The University of Melbourne, Victoria, 3010, Australia
  • Genevieve Klug Florey Institute, The University of Melbourne, Victoria, 3010, Australia
  • Catriona McLean Florey Institute, The University of Melbourne, Victoria, 3010, Australia; Alfred Hospital, Department of Anatomical Pathology, 55 Commercial Rd, Melbourne Vic 3004 Australia
  • Colin L Masters Florey Institute, The University of Melbourne, Victoria, 3010, Australia
  • Steven Collins Department of Medicine, The University of Melbourne, Victoria, 3010, Australia

DOI:

https://doi.org/10.33321/cdi.2022.46.53

Keywords:

Creutzfeldt-Jakob disease, prion disease, transmissible spongiform encephalopathy, disease surveillance

Abstract

Nationwide surveillance of Creutzfeldt-Jakob disease (CJD) and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable developments have occurred in pre-mortem diagnostics; in the delineation of new disease subtypes; and in a heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2021.
Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2021, a total of 548 domestic CSF specimens were referred for 14-3-3 protein testing; 73 persons with suspected human prion disease were formally added to the national register. As of 31 December 2021, just over half of the 73 suspect case notifications (37/73) remain classified as ‘incomplete’; 17 cases were classified as ‘definite’ and 13 as ‘probable’ prion disease; six cases were excluded through either detailed clinical follow-up (two cases) or neuropathological examination (four cases). For 2021, sixty-four percent of all suspected human-prion-disease-related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified.

Downloads

Download data is not yet available.

References

Klug GM, Boyd A, Zhao T, Stehmann C, Simpson M, McLean CA et al. Surveillance for Creutzfeldt-Jakob disease in Australia: update to December 2012. Commun Dis Intell Q Rep. 2013;37(2):E115–20.

Allars M. Report of the inquiry into the use of pituitary derived hormones in Australia and Creutzfeldt-Jakob disease. Canberra: AGPS, 1994.

Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(10):2659–68. doi: https://doi.org/10.1093/brain/awp191.

Creutzfeldt-Jakob Disease International Surveillance Network: Surveillance Data. [Internet.] Solna: European Centre for Disease Prevention and Control; 2021. Available from: https://www.eurocjd.ed.ac.uk/data_tables.

Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis. 2020;20(1):e2–10. doi: https://doi.org/10.1016/S1473-3099(19)30615-2.

Klug GM, Wand H, Simpson M, Boyd A, Law M, Masters CL et al. Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry. 2013;84(2):1372–7. doi: https://doi.org/10.1136/jnnp-2012-304820.

Roche Diagnostics. The power of Elecsys® in Alzheimer’s disease. [Internet.] Basel: Roche Diagnostics; 2022. Available from: https://diagnostics.roche.com/global/en/article-listing/health-topics/neurology/the-power-of-elecsys-in-alzheimers-disease.html.

Australian Bureau of Statistics. National, state and territory population - reference period June 2021. [Webpage.] Canberra: Australian Bureau of Statistics; 16 December 2021. [Accessed on 2 February 2022.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/jun-2021#data-download.

Holper S, Lewis V, Wesselingh R, Gaillard F, Collins SJ, Butzkueven H. Comprehensive clinical, radiological, pathological and biochemical analysis required to differentiate VV1 sporadic Creutzfeldt-Jakob disease from suspected variant CJD. BMJ Neurol Open. 2022;4(1):e000299. doi: https://doi.org/10.1136/bmjno-2022-000299.

Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol. 2008;63(6):697–708. doi: https://doi.org/10.1002/ana.21420.

Notari S, Appleby BS, Gambetti P. Variably protease-sensitive prionopathy. Handb Clin Neurol. 2018;153:175–90. doi: https://doi.org/10.1016/B978-0-444-63945-5.00010-6.

Schmitz M, Villar-Piqué A, Hermann P, Escaramís G, Calero M, Chen C et al. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain. 2022;145(2):700–12. doi: https://doi.org/10.1093/brain/awab350.

Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A. Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet. 2002;360(9327):139–41. doi: https://doi.org/10.1016/S0140-6736(02)09384-4.

Klug GM, Wand H, Boyd A, Law M, Whyte S, Kaldor J et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain. 2009:132(2);493–501. doi: https://doi.org/10.1093/brain/awn303.

Collins S, Boyd A, Fletcher A, Kaldor J, Hill A, Farish S et al. Creutzfeldt-Jakob disease cluster in an Australian rural city. Ann Neurol. 2002;52(1):115–8. doi: https://doi.org/10.1002/ana.10224.

Stevenson M, Uttley L, Oakley JE, Carroll C, Chick SE, Wong R. Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review. Health Technol Assess. 2020;24(11):1–150. doi: https://doi.org/10.3310/hta24110.

The Royal College of Pathologists of Australasia Autopsy Working Party. The decline of the hospital autopsy: a safety and quality issue for healthcare in Australia. Med J Aust. 2004;180(6):281–5. doi: https://doi.org/10.5694/j.1326-5377.2004.tb05926.x.

Jackett L, McLean C. Hospital autopsy audit: discordant primary clinical diagnoses are found in 20% of cases in a reducing autopsy case load. Selection bias or significant findings? Pathology. 2015;47(6):499–502. doi: https://doi.org/10.1097/PAT.0000000000000297.

Panegyres PK, Stehmann C, Klug GM, Masters CL, Collins S. Prion disease in Indigenous Australians. Intern Med J. 2020. doi: https://doi.org/10.1111/imj.14835.

Japanese CJD Surveillance Unit. Personal communication.

Mok T, Jaunmuktane Z, Joiner S, Campbell T, Morgan C, Wakerley B et al. Variant Creutzfeldt–Jakob disease in a patient with heterozygosity at PRNP codon 129. N Engl J Med. 2017;376(3):292–4. doi: https://doi.org/10.1056/NEJMc1610003.

Watson N, Brandel JP, Green A, Hermann P, Ladogana A, Lindsay T et al. The importance of ongoing international surveillance for Creutzfeldt-Jakob disease. Nat Rev Neurol. 2021;17(6):362–79. doi: https://doi.org/10.1038/s41582-021-00488-7.

Brandel JP, Vlaicu MB, Culeux A, Belondrade M, Bougard D, Grznarova K et al. Variant Creutzfeldt–Jakob disease diagnosed 7.5 years after occupational exposure. N Engl J Med. 2020;383(1):83–5. doi: https://doi.org/10.1056/NEJMc2000687.

Brandel JP. Personal communication; February 2022.

Alnakhli SH, Wand H, Law M, Sarros S, Stehmann C, Senesi M et al. Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. J Clin Neurosci. 2020;81:78–82. doi: https://doi.org/ 10.1016/j.jocn.2020.09.021.

Cali I, Cohen ML, Haїk S, Parchi P, Giaccone G, Collins SJ et al. Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study. Acta Neuropathol Commun. 2018;6(1):5. doi: https://doi.org/10.1186/s40478-017-0503-z.

Purro SA, Farrow MA, Linehan J, Nazari T, Thomas DX, Chen Z et al. Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone. Nature. 2018;564(7736):415–9. doi: https://doi.org/10.1038/s41586-018-0790-y.

Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, Koriath C et al. Evidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathol. 2018;135(5):671–9. doi: https://doi.org/10.1007/s00401-018-1822-2.

Banerjee G, Adams ME, Jaunmuktane Z, Lammie GA, Turner B, Wani M et al. Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann Neurol. 2019;85(2):284–90. doi: https://doi.org/10.1002/ana.25407.

Downloads

Published

18/08/22

How to Cite

Stehmann, Christiane, Matteo Senesi, Shannon Sarros, Amelia McGlade, Victoria Lewis, Marion Simpson, Genevieve Klug, Catriona McLean, Colin L Masters, and Steven Collins. 2022. “Creutzfeldt-Jakob Disease Surveillance in Australia: Update to 31 December 2021”. Communicable Diseases Intelligence 46 (August). https://doi.org/10.33321/cdi.2022.46.53.

Issue

Vol. 46 (2022)

Section

Annual report

Categories

License

Copyright (c) 2022 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

<< < 1 2 3